Adoptive immunotherapy of cancer with macrophages: current approaches and further prospectsKELLER, R.European journal of cancer & clinical oncology. 1989, Vol 25, Num 4, pp 599-601, issn 0277-5379Article

Adoptive immunotherapy of cancer: accomplishments and prospects = Immunothérapie adoptive du cancer: résultats et perspectivesROSENBERG, S. A.Cancer treatment reports. 1984, Vol 68, Num 1, pp 233-255, issn 0361-5960Article

IMMUNOTHERAPY OF CANCER WITH "IMMUNE" RNA. A PRELIMINARY REPORT.PILCH YH; DE KERNION JB; SKINNER DG et al.1976; AMER. J. SURG.; U.S.A.; DA. 1976; VOL. 132; NO 5; PP. 631-637; BIBL. 26 REF.Article

THE ELEVATION OF ADOPTIVE RESPONSES TO SHEEP ERYTHROCYTES IN PROTEIN-DEFICIENT MICE.PRICE P.1978; IMMUNOLOGY; GBR; DA. 1978; VOL. 35; NO 3; PP. 531-537; BIBL. 10 REF.Article

IMMUNE RNA IN THE IMMUNOTHERAPY OF CANCER.PILCH YH; FRITZE D; KERN DH et al.1976; MED. CLIN. N. AMER.; U.S.A.; DA. 1976; VOL. 60; NO 3; PP. 567-583; BIBL. 30 REF.Article

The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cellsDENICOFF, K. D; RUBINOW, D. R; PAPA, M. Z et al.Annals of internal medicine. 1987, Vol 107, Num 3, pp 293-300, issn 0003-4819Article

Low deformability of lymphokine-activated killer cells as a possible determinant of in vivo distributionSASAKI, A; JAIN, R. K; MAGHAZACHI, A. A et al.Cancer research (Baltimore). 1989, Vol 49, Num 14, pp 3742-3746, issn 0008-5472Article

Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancerKRADIN, R. L; KURNICK, J. T; STRAUSS, H. W et al.Lancet (British edition). 1989, Num 8638, pp 577-580, issn 0140-6736Article

Lymphokine activated killer cellsLINDEMANN, A; HERRMANN, F; OSTER, W et al.Blut. 1989, Vol 59, Num 4, pp 375-384, issn 0006-5242Article

Immunothérapie adoptive par interleukine-2: premiers résultats d'une étude pilote chez 6 malades cancéreux = Adoptive immunotherapy by interleukine-2: preliminary results of a pilot study in 6 patients with cancerSCULIER, J. P; BRON, D; DELFORGE, A et al.La Presse médicale (1983). 1989, Vol 18, Num 23, pp 1155-1158, issn 0755-4982, 4 p.Article

Adoptive immunotherapy in conjunction with bone marrow transplantation ― Amplification of natural host defence mechanisms against cancer by recombinant IL-2SLAVIN, S; ECKERSTEIN, A; WEISS, L et al.Natural immunity and cell growth regulation. 1988, Vol 7, Num 3, pp 180-184, issn 0254-7600Article

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancerWEST, W. H; TAUER, K. W; YANNELLI, J. R et al.The New England journal of medicine. 1987, Vol 316, Num 15, pp 898-905, issn 0028-4793Article

Immunothérapie adoptive: une nouvelle approche thérapeutique = Adoptive immunotherapy: a new therapeutic approachIRLE, C; MARTINEZ, E.Médecine et hygiène. 1986, Vol 44, Num 1678, pp 3126-3132, issn 0025-6749, 5 p.Article

Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenograftsMURPHY, W. J; BACK, T. C; CONLON, K. C et al.The Journal of clinical investigation. 1993, Vol 92, Num 4, pp 1918-1924, issn 0021-9738Article

Immunomodulation of neoplasia by interleukin 2ROSSIO, J. L; RUSCETTI, F. W.Progress in experimental tumor research. 1988, Vol 32, pp 174-186, issn 0079-6263Article

Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour: evidence that Cy permits the expression of adoptive T-cell mediated by removing suppressor T cells rather than by reducing tumour burdenAWWAD, M; NORTH, R. J.Immunology (Oxford). 1988, Vol 65, Num 1, pp 87-92, issn 0019-2805Article

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 aloneROSENBERG, S. A; LOTZE, M. T; SEIPP, C. A et al.The New England journal of medicine. 1987, Vol 316, Num 15, pp 889-897, issn 0028-4793Article

γ-Irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cellsNORTH, R. J.Cancer immunology and immunotherapy. 1984, Vol 16, Num 3, pp 175-181, issn 0340-7004Article

Adoptive transfer of immunity by spleen cells from LSA-lymphoma mice cured by BCNU = Transfert adoptif de l'immunité par les cellules spléniques de souris porteuses de lymphome LSA guéries par la BCNUMARUYAMA, Y; WILLIAMS, A. C; FEOLA, J. M et al.Leukemia research. 1984, Vol 8, Num 4, pp 629-636, issn 0145-2126Article

Murine malaria: cellular interactions in the immune responseSTRICKLAND, G. T; AHMED, A; SAYLES, P. C et al.The American journal of tropical medicine and hygiene. 1983, Vol 32, Num 6, pp 1229-1235, issn 0002-9637Article

Activated and memory T lymphocytes in human milkWIRT, D. P; ADKINS, L. T; PALKOWETZ, K. H et al.Cytometry (New York, N.Y.). 1992, Vol 13, Num 3, pp 282-290, issn 0196-4763Article

Bryostatin 1-activated T cells can traffic and mediate tumor regressionTUTTLE, T. M; BETHKE, K. P; INGE, T. H et al.The Journal of surgical research. 1992, Vol 52, Num 6, pp 543-548, issn 0022-4804Conference Paper

IL-2: nursing applications in a developing sciencePADAVIC-SHALLER, K.Seminars in oncology nursing. 1988, Vol 4, Num 2, pp 142-150, issn 0749-2081Article

Cellules LAK et immunothérapie des cancers = LAK cells and cancer immunotherapyKHAYAT, D; WEIL, M; SOUBRANE, C et al.Bulletin du cancer. 1988, Vol 75, Num 1, pp 3-7, issn 0007-4551Article

Antibody levels in adoptively immunized mice after injection with Babesia microti or injection with antigen fractionsMEEUSEN, E; LLOYD, S; SOULSBY, E. J. L et al.Australian journal of experimental biology and medical science. 1985, Vol 63, Num 3, pp 261-272, issn 0004-945XArticle